Background: Expression of allergens in human cells is a prerequisite for the development of antigen-specific cell therapy in IgE-mediated allergy. We developed a strategy how the clinically relevant major grass pollen allergen Phl p 5 can be efficiently secreted or expressed on the surface of human cells with preserved allergenic activity. Methods: The cDNA of Phl p 5 was fused to a leader peptide with or without a transmembrane domain and both constructs were ligated into a mammalian expression vector. Transfection of these plasmids into human cells resulted in a membrane-anchored or secreted version of Phl p 5, respectively, as determined by ELISA or flow cytometric analysis. Results: Both the secreted and membrane-anchored Phl p 5 proteins bound IgE from allergic patients in an immunoblot assay and induced specific histamine release and CD203c upregulation in basophils of grass pollen-allergic patients. Proliferation of peripheral blood mononuclear cells from Phl p 5-allergic individuals was induced upon stimulation with both variants of Phl p 5 expressed in human cells similar to recombinant Phl p 5. Conclusions: Secreted and membrane-anchored Phl p 5 expressed in human cells preserved B cell as well as T cell epitopes and may be used to develop and test various cell-based strategies for allergen-specific immunomodulation and to delineate the tolerance mechanisms involved therein.

Keywords:
IgE-mediated allergy, Recombinant allergen Phl p 5, Cell-based therapy, Allergenic activity, Surface protein expression
1.
Bagley J, Bracy J, Tian C, Kang ES, Iacomini J: Establishing immunological tolerance through the induction of molecular chimerism. Front Biosci 2002;7:1333–1337.
2.
Baranyi U, Pilat N, Gattringer M, Wekerle T: A chimerism-based approach to induce tolerance in IgE-mediated allergy. Crit Rev Immunol 2009;29:379–397.
3.
Pomès A: Relevant B cell epitopes in allergic disease. Int Arch Allergy Immunol 2010;152:1–11.
4.
Valenta R, Kraft D: Recombinant allergen molecules: tools to study effector cell activation. Immunol Rev 2001;179:119–127.
5.
Valenta R, Ferreira F, Focke-Tejkl M, Linhart B, Niederberger V, Swoboda I, Vrtala S: From allergen genes to allergy vaccines. Annu Rev Immunol 2010;28:211–241.
6.
Vrtala S, Sperr W, Reimitzer I, van Ree R, Laffer S, Muller W, Valent P, Lechner K, Rumpold H, Kraft D: cDNA cloning of a major allergen from timothy grass (Phleum pratense) pollen: characterization of the recombinant Phl pV allergen. J Immunol 1993;151:4773–4781.
7.
Ho SN, Hunt HD, Horton RM, Pullen JK, Pease LR: Site-directed mutagenesis by overlap extension using the polymerase chain reaction. Gene 1989;77:51–59.
8.
Pear WS, Nolan GP, Scott ML, Baltimore D: Production of high-titer helper-free retroviruses by transient transfection. Proc Natl Acad Sci USA 1993;90:8392–8396.
9.
Baranyi U, Linhart B, Pilat N, Gattringer M, Bagley J, Muehlbacher F, Iacomini J, Valenta R, Wekerle T: Tolerization of a type I allergic immune response through transplantation of genetically modified hematopoietic stem cells. J Immunol 2008;180:8168–8175.
10.
Valenta R, Duchene M, Ebner C, Valent P, Sillaber C, Deviller P, Ferreira F, Tejkl M, Edelmann H, Kraft D, Scheiner O: Profilins constitute a novel family of functional plant pan-allergens. J Exp Med 1992;175:377–385.
11.
Focke M, Marth K, Flicker S, Valenta R: Heterogeneity of commercial timothy grass pollen extracts. Clin Exp Allergy 2008;38:1400–1408.
12.
Valent P, Hauswirth AW, Natter S, Sperr WR, Buehring HJ, Valenta R: Assays for measuring in vitro basophil activation induced by recombinant allergens: recombinant allergens. Methods 2004;32:265–270.
13.
Chesnut JD, Baytan AR, Russell M, Chang MP, Bernard A, Maxwell IH, Hoeffler JP: Selective isolation of transiently transfected cells from a mammalian cell population with vectors expressing a membrane anchored single-chain antibody. J Immunol Methods 1996;193:17–27.
14.
Bischoff SC: Role of mast cells in allergic and non-allergic immune responses: comparison of human and murine data. Nat Rev Immunol 2007;7:93–104.
15.
Vrtala S, Susani M, Sperr WR, Valent P, Laffer S, Dolecek C, Kraft D, Valenta R: Immunologic characterization of purified recombinant timothy grass pollen (Phleum pratense) allergens (Phl p 1, Phl p 2, Phl p 5). J Allergy Clin Immunol 1996;97:781–787.
16.
Valenta R: The future of antigen-specific immunotherapy of allergy. Nat Rev Immunol 2002;2:446–453.
17.
Klostermann B, Bellinghausen I, Boettcher I, Petersen A, Becker WM, Knop J, Saloga J: Modification of the human allergic immune response by allergen-DNA-transfected dendritic cells in vitro. J Allergy and Clin Immunol 2004;113:327–333.
© 2011 S. Karger AG, Basel
2011
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.